Infliximab biosimilar - Merck & Co./Samsung Bioepis

Drug Profile

Infliximab biosimilar - Merck & Co./Samsung Bioepis

Alternative Names: Flixabi; Infliximab - Samsung Bioepis; Infliximab-abda; RENFLEXIS; SB 2

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Samsung Bioepis
  • Developer Merck & Co; Samsung Bioepis
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Antiulcers
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 13 Jun 2018 Pooled efficacy data from a phase III trial in Rheumatoid Arthritis presented at the 19th Annual Congress of the European League Against Rheumatism
  • 24 Jul 2017 Launched for Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis, Ulcerative colitis, Crohn's disease and Rheumatoid arthritis in USA (IV)
  • 14 Jun 2017 Efficacy data from a phase III trial in Rheumatoid arthritis presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top